YOLFTbeta
SillaJen Inc

SillaJen Inc

215600 · KQ · Healthcare / Biotechnology

1,896.00KRW-10.00 (-0.52%)

Price History

Full chart

Market Stats

Previous Close1,906.00
Open1,902.00
Day Range1,894.00 – 1,938.00
52-Week Range1,780.00 – 5,400.00
Volume464.47K
Market Cap327.37B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.05
50-Day Avg2,285.62
200-Day Avg3,018.09

About

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jaekyung Kim
  • Employees57
  • Headquarters106 Cheonggyecheon-ro, Seoul, South Korea, 04542, Korea
  • Websitehttps://www.sillajen.com

Leadership

  • Mr. Jaekyung KimCEO & Chairman of the Board · b. 1964
  • Mr. TaeGyun KimPresident · b. 1963
  • Suk Song MyungChief Financial Officer
  • Mr. Eun-Ki MinChief Accounting Officer and Executive Director
  • Chan Kwon Hyuk M.D., Ph.D.Chief Medical Officer
  • Mee Yang Kyung Ph.D.Head of R&D Strategic Planning
  • Mr. Jaejeong LeeExecutive Officer · b. 1971
  • Mr. Jeongseok LeeExecutive Officer · b. 1982
  • Mr. SangGeun ParkExecutive Director · b. 1976
  • Mr. SeungHwan ChoExecutive Officer · b. 1978

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue01.81B5.29B6.86B7.71B-1.67B254.36M5.01B3.94B3.93B9.23B
Growth (%)--+192.42%+29.71%+12.34%---84.77%+1870.95%-21.42%-0.33%+134.94%
Cost of Revenue00000---3.53B2.48B3.20B3.94B
Gross Profit01.81B5.29B6.86B7.71B-1.67B254.36M1.48B1.46B727.29M5.29B
Gross Margin-100.00%100.00%100.00%100.00%-100.00%100.00%29.58%36.98%18.52%57.32%
Operating Expense23.77B25.58B52.12B57.48B66.99B-47.88B20.60B25.98B22.80B28.85B31.61B
Operating Income-23.77B-23.77B-46.82B-50.62B-59.28B--46.21B-20.35B-24.50B-21.34B-28.12B-26.32B
Operating Margin--1313.62%-884.76%-737.35%-768.66%--2767.55%-8000.41%-488.71%-541.78%-716.20%-285.30%
EBITDA---------20.62B-17.35B-23.69B-22.11B
EBITDA Margin---------411.38%-440.47%-603.23%-239.63%
Net Income0-55.85B-74.04B-57.02B-56.24B--47.82B-15.31B-25.26B-20.37B-26.53B-24.19B
Net Income Margin--3086.09%-1398.97%-830.62%-729.20%--2864.25%-6017.12%-503.80%-517.04%-675.53%-262.21%
R&D---33.18B--------
R&D as % of Total Revenue---483.35%--------
Interest Expense0000001.68B2.81B2.08B1.68B1.82B903.40M
Interest Expense % of Total Revenue-0.00%0.00%0.00%0.00%-100.39%1104.64%41.47%42.72%46.23%9.79%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets153.03B284.13B234.95B193.19B-47.42B134.83B103.45B76.71B149.02B116.81B
Total Liabilities66.09B76.16B33.01B28.11B-24.54B26.78B24.51B19.40B17.20B6.69B
Total Equity86.94B207.97B201.95B165.09B-22.88B108.05B78.94B57.31B131.82B110.12B
Cash55.31B30.64B40.23B23.90B-4.49B49.07B12.63B23.59B81.30B5.28B
Net Debt-----8.59B-1.79B---

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-22.39B-22.39B-197.98B33.83B-48.43B-6.54B-22.94B-60.69B-22.14B-17.02B-17.83B-22.50B
Investing Cash Flow31.93B31.93B-20.35B-29.38B25.48B-8.73B-740.33M8.40B-10.22B36.33B-25.29B-
Financing Cash Flow-5.63B-5.63B193.12B6.09B6.19B-917.35M20.33B96.83B-4.08B-8.35B100.56B-
Capital Expenditure3.14B3.14B312.77M783.70M282.68M791.98M73.61M64.57M291.70M360.85M234.47M3.72B
Free Cash Flow-----14.79B-23.04B-60.77B-41.59B-17.38B-18.06B-26.22B
FCF to OCF------226.28%100.44%100.12%187.87%102.12%101.32%116.53%

Earnings

Report DateMar 15, 2017May 31, 2017Aug 11, 2017Nov 14, 2017Mar 15, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Mar 19, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 2, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Aug 14, 2023Nov 14, 2023Mar 21, 2024May 16, 2024Aug 13, 2024Nov 12, 2024Feb 21, 2025May 15, 2025Aug 11, 2025Nov 12, 2025Dec 31, 2025May 13, 2026Jun 30, 2026
EPS Estimate---------------------------------------
EPS Actual-760.00-186.15-294.94-146.17-250.00-207.11-194.29-248.00-163.00-218.00-1002.11-220.37-162.73-134.12-227.86-184.87-60.20-61.3920.55-50.19-68.22-52.55-43.94-53.58-73.05-31.83-51.29-51.92-57.96-45.59-64.07-57.30-50.14-36.18-39.89-42.55-56.72-35.54-39.62
Surprise---------------------------------------
TimingPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hours-------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap327.37B
Enterprise Value242.45B
Trailing P/E0.00
Forward P/E0.00
Price / Sales30.39
Price / Book3.08
Revenue (TTM)10.77B
Gross Profit (TTM)7.47B
EBITDA-25.19B
Profit Margin-223.82%
Operating Margin-275.55%
Return on Equity-21.50%
Return on Assets-13.67%
Shares Outstanding138.13M
Shares Float119.74M
Beta0.05
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 9, 20241591:1445